Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838795 | 0.84 | AKR1C3 (0.55) | MAPTGAAAKR1C3ALDH1A1KMT2A | |
| SCHEMBL9236867 | 0.82 | MAPT (0.51) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| SCHEMBL2760394 | 0.77 | GAA (0.58) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| Benzene SCHEMBL28303083 | 0.77 | MAPT (0.74) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| SCHEMBL29786713 | 0.77 | MAPT (0.74) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| SCHEMBL2690787 | 0.77 | AKR1C3 (0.67) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| SCHEMBL112508 | 0.77 | MAPT (0.74) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28386096 | 0.76 | MAPT (0.56) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| SCHEMBL5807536 | 0.75 | MAPT (0.60) | MAPTGAAAKR1C3LMNAALDH1A1 | |
| SCHEMBL28282156 | 0.75 | MAPT (0.71) | MAPTGAAAKR1C3LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-1309323-B1 | TREATMENT OF ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID DERIVATIVES | ALCON INC (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-1309322-B1 | USE OF 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISORDERS | ALCON INC (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050143468-A1 | Method of treating vascular endothelial growth factor mediated vascular disorders | ALCON, INC. (CH) | 2005-06-30 | — | — | US | disclosed |
| EP-1507522-A2 | METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISORDERS USING AMFENAC OR NEPAFENAC | Alcon, Inc. (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALCON, INC. (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2003092669-A2 | METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISORDERS USING AMFENAC OR NEPAFENAC | ALCON, INC. (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20030207941-A1 | Method of treating vascular endothelial growth factor mediated vascular disorders | ALCON, INC. (CH) | 2003-11-06 | — | — | US | disclosed |
| US-6638976-B2 | 3-benzoylphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders | ALCON, INC. (CH) | 2003-10-28 | — | — | US | disclosed |
| US-20030187072-A1 | Method of treating angiogenesis-related disorders | ALCON, INC. (CH) | 2003-10-02 | — | — | US | disclosed |
| EP-1309322-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | Alcon, Inc (CH) | 2003-05-14 | — | — | EP | disclosed |
| EP-1309323-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | Alcon Inc. (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-20020049255-A1 | Method of treating neurodegenerative disorders of the retina and optic nerve head | ALCON UNIVERSAL LTD. | 2002-04-25 | — | — | US | disclosed |
| EP-0716600-B1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LAB INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | ALCON UNIVERSAL LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2002013805-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002013804-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | disclosed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049255-A1 | Method of treating neurodegenerative disorders of the retina and optic nerve head | NLN, ALDH1A2, GAP43 | MAPT 480/4885GAA 349/4885AKR1C3 478/4885 |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | FLT1, TEK, FLT4 | MAPT 2905/4885GAA 3191/4885AKR1C3 1330/4885 |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALDH1A2, GAP43, NLN | MAPT 1929/4885GAA 302/4885AKR1C3 802/4885 |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | MAPT 3273/4885GAA 887/4885AKR1C3 262/4885 |
| US-20030187072-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | MAPT 3273/4885GAA 887/4885AKR1C3 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.